The award will support the Center for Data Science and Artificial Intelligence in developing an AI-powered system to help identify personalized treatment options for children with cancer.

Solid tumors resist CAR cell therapy through antigen heterogeneity, poor infiltration, and an immunosuppressive microenvironment. A new review argues that oncolytic viruses and CAR cells should be co-designed as an integrated, self-amplifying therapeutic system rather than simply combined. The authors describe how oncolytic viruses can install new targets, remodel the tumor microenvironment, and deliver local immune support, outlining engineering strategies, translational challenges, and future directions for next-generation solid tumor immunotherapy.

A team led by researchers at Peking University Cancer Hospital & Institute reports that combining targeted KRAS inhibition with CTLA-4 immune checkpoint blockade overcomes the immunosuppressive microenvironment that renders KRAS-mutant gastric adenocarcinoma resistant to PD-1 immunotherapy. In a genetically faithful, immunocompetent mouse model of KRAS^G12D-driven gastric cancer, the combination suppressed TGF-beta signaling, impaired regulatory T cell function and elicited effective anti-tumor immunity. The study, published in Science China Life Sciences, provides a preclinical rationale for CTLA-4-based combination immunotherapy in this molecularly defined subset of patients.

Tony Hunter receives the 2026 Albany Prize in Medicine and Biomedical Research in recognition of his tyrosine phosphorylation discovery in 1979, which paved the way for 100+ cancer drugs. The award celebrates scientists whose research has led to treatments that significantly improve patients’ lives and comes with a $500,000 prize.